PracticeUpdate: Oncology - Winter 2018

First page Table of contents Next page Last page
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer7
Ribociclib Plus Endocrine Therapy for Premenopausal Women With HR+ Advanced Breast Cancer8
Pembrolizumab vs Paclitaxel for Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer9
Clinical Consequences of Chemotherapy Dose Reduction in Obese Patients With Stage III Colon Cancer10
Progression-Free Survival at 24 Months and Subsequent Outcomes for Patients With DLBCL11
Immune Recognition of Somatic Mutations Leading to Complete Durable Regression in Metastatic Breast Cancer11
Sunitinib Alone or After Nephrectomy in Renal Cell Carcinoma12
Circulating Tumor Cell Status Predicts Radiotherapy Benefit in Early Breast Cancer13
Three-Month Post-Treatment PSA Level as a Biomarker of Treatment Response in Patients With Intermediate- or High-Risk Prostate Cancer Treated With ADT and RT14
Male Breast Cancer: An Updated SEER Data Analysis15
Intravesical Instillation of Gemcitabine vs Saline After Resection of Suspected Low-Grade Non-Muscle Invasive Bladder Cancer16
Risk Stratification of Smoldering Multiple Myeloma Incorporating Revised IMWG Diagnostic Criteria17
Efficacy and Safety of ABP 980 Compared With Reference Trastuzumab in HER2+ Early Breast Cancer18
10 Practice Changes That I Will Make After Attending ASCO 201820
Top 3 Advances in Radiation Oncology From ASCO 201822
Lung Cancer Studies at ASCO 201824
ASCO 2018: Best in Ovarian Cancer25
Multiple Myeloma at ASCO 201826
ASCO 2018: Updates on PARP Inhibitors in Prostate Cancer26
Mirtazapine Prevents Delayed Nausea and Vomiting in Highly Emetogenic Chemotherapy27
Patients With Advanced Cancer May Not Have to Accept Anorexia as Inevitable28
Shorter Trastuzumab Treatment for HER2- Positive Breast Cancer Can Be as Effective, With Fewer Cardiac Side Effects29
Consider Obinutuzumab Plus Chlorambucil for First-Line Treatment for CLL30
Neither Myeloablative nor Reduced-Intensity Conditioning Impact Overall Survival in T-Cell Lymphoma31
Response Rates Improve Significantly With Three-Drug Combination for DLBCL32
EUTOS Long-Term Survival Score Superior for Prognosis of Survival in CML33
Rituximab Yields Durable Response in Adults With Persistent or Chronic Immune Thrombocytopenia34

Made with FlippingBook Online newsletter